Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

By sjmartinez • April 18, 2024

Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, Photowala H, Kaplan B, Kristensen LE. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18. PMID: 38632977.

Tags: Biologics, Dermatology, interleukin-23, psoriatic arthritis, Publications, risankizumab

Emergency vs. Outpatient Care for Pediatric Atopic Dermatitis: A Population-Based Study of Sociodemographic Factors and Healthcare Utilization

Yamamoto RK, Tolson HC, Hao A, Kikuchi R, Sadrolashrafi K, Guo L, Bilimoria SN, Yee D, Armstrong AW. Emergency vs. Outpatient Care for Pediatric Atopic[...]

Beyond Universalis: eyebrow and eyelash loss in patients with alopecia areata

Fu J, Goh C. Beyond Universalis: eyebrow and eyelash loss in patients with alopecia areata. Br J Dermatol. 2025 Apr 11:ljaf139. doi: 10.1093/bjd/ljaf139. Epub ahead[...]

Measles Resurgence: What Every Dermatologist Should Know

Freeman E, Li C, Castillo D, Ahuja S, Chiu YE, Elewski B, Goh C, Hu J, Rosmarin D, Trinidad J, Rosenbach M. Measles Resurgence: What[...]